International Edition
Latest News
Health

Aggressive Metastasis-Directed Therapy Does Not Improve Survival in Oligometastatic Breast Cancer, NRG-BR002 Trial Finds

Aggressive treatment of all visible metastases with radiation or surgery failed to extend survival for patients with oligometastatic breast cancer already receiving effective systemic therapy, according to final results of the NRG-BR002 trial published in the Journal of…

Aggressive Metastasis-Directed Therapy Does Not Improve Survival in Oligometastatic Breast Cancer, NRG-BR002 Trial Finds

Aggressive treatment of all visible metastases with radiation or surgery failed to extend survival for patients with oligometastatic breast cancer already receiving effective systemic therapy, according to final results of the NRG-BR002 trial published in the Journal of Clinical Oncology.

The multicenter, randomized Phase 2/3 trial enrolled 129 patients at 47 institutions in the United States and Canada, with 125 eligible for analysis. Participants had four or fewer metastatic tumors and were assigned to standard first-line systemic therapy alone or systemic therapy plus metastasis-directed ablation with stereotactic body radiation therapy (SBRT) or surgery. The final analysis, with nearly twice the follow-up of the 2022 preliminary report, showed no significant improvement in progression-free or overall survival, Newswise reported.

“Radiating asymptomatic tumors for most patients in this setting doesn’t seem to help people and certainly doesn’t help with overall survival,” said Nora Jaskowiak, MD, a breast surgeon at UChicago Medicine who served as the trial’s surgical principal investigator. “Some of that is likely because systemic treatment in breast cancer right now is so effective at controlling this disease.”

Steven J. Chmura, MD, PhD, the trial’s principal investigator and inaugural Chair of Breast Radiation Oncology at the University of Texas MD Anderson Cancer Center, said the study demonstrates that more treatment is not always better — especially when it adds time, cost, and potential long-term side effects without improving survival. He noted that median progression-free survival and overall survival outcomes “clearly exceeded anything we had hoped for” in both arms, reflecting dramatic advances in systemic therapies such as CDK4/6 inhibitors, antibody-drug conjugates, and PD-L1 immunotherapy during the trial’s enrollment period.

The oligometastasis hypothesis — proposed in 1995 by University of Chicago radiation oncologists Ralph Weichselbaum, MD, and Samuel Hellman, MD — posited that an intermediate state of limited metastatic spread could be cured by aggressively targeting individual tumors.

While randomized trials have validated metastasis-directed therapy in certain oligometastatic cancers, NRG-BR002 is the first such trial in breast cancer to provide evidence against routinely adding local ablation when systemic therapy is controlling the disease, according to UChicago Medicine.

An exploratory analysis of circulating tumor cells (CTCs) before treatment offered a potential path forward. Patients with low or undetectable CTCs experienced longer progression-free survival, while those with higher CTC levels did not. “This gives us the first signal that the number of metastases coupled with a biologic signature could potentially identify the patients most likely to benefit from radiating metastases, but that would need to be tested in another trial before it could be adopted in routine clinical practice,” Jaskowiak said.

Chmura said the results “point us towards the correct door” by showing that simply counting metastatic lesions may not be enough to select patients for aggressive local therapy.

Future trials will need to combine metastatic burden with blood-based biomarkers such as CTCs and circulating tumor DNA to define biologically oligometastatic disease.

Separately, research from Duke Cancer Institute published in JAMA Surgery using National Cancer Database data suggested that surgery to remove the primary breast tumor — not treatment of distant metastatic sites — was the factor most strongly associated with improved survival in select patients with limited metastatic disease.

“What stood out was that removing the primary breast tumor seemed to be the factor most strongly associated with improved survival,” said Jennifer Plichta, MD, a breast surgical oncologist at Duke Cancer Institute. “Treating the distant sites did not appear to offer the same survival advantage on its own.”

The NRG-BR002 study was supported by the National Cancer Institute, the Ludwig Foundation for Cancer Research, and the Breast Cancer Research Foundation.

About the author: Health Desk

Health Desk at Archynewsy.